Status:
ACTIVE_NOT_RECRUITING
The Engaging Primary Care in Cancer Survivorship (EPICS) Study
Lead Sponsor:
Kaiser Permanente
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Colorectal Cancer
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
A quasi-experimental non-randomized pre/post with control group trial of two models of cancer survivorship care in early-stage colorectal and breast cancer survivors cared for in a community-based, in...
Detailed Description
A quasi-experimental non-randomized pre/post with control group trial of two models of cancer survivorship care in early-stage colorectal and breast cancer survivors cared for in a community-based, in...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients: Adult (21+) Kaiser Permanente Southern California members diagnosed and treated for pathologically confirmed first primary early-stage breast (stage 0, I, II) or colorectal (stage I, II) cancer within Kaiser Permanente Southern California. Completed active cancer treatment within the past 6-36 months; active treatment includes cancer-directed surgery, chemotherapy (includes Herceptin (Trastuzumab)), radiation therapy, and ovarian suppression therapy (e.g., Goserelin (Zoladex)). Completed at least one office visit within Kaiser Permanente Southern California medical oncology. At low-risk for cancer recurrence and treatment-related toxicities based on state of disease and treatment modalities. For our Aim 2 survey: Primary language of English or Spanish (although we will assess our Aim 1 participants for recorded preferred spoken language and adjust translations as needed). Ability to complete surveys of patient-reported outcomes.
- Physicians: For centers assigned to the embedded primary care physician (PCP) model, PCPs selected to participate must be Board Certified in a relevant primary care specialty; hold a valid and current MD or advanced practitioner license; and be employed by the Southern California Permanente Medical Group.
- Exclusion criteria:
- Patients less than 21 years of age
- Patients at high risk for recurrence and treatment-related toxicities based on stage of disease and treatment modalities
Exclusion
Key Trial Info
Start Date :
September 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
2450 Patients enrolled
Trial Details
Trial ID
NCT04745754
Start Date
September 21 2021
End Date
February 28 2026
Last Update
December 12 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Orange County Anaheim/Irvine Medical Center Oncology Clinics
Anaheim, California, United States, 92806
2
Kaiser Permanente Baldwin Park Medical Center Oncology Clinic
Baldwin Park, California, United States, 91706
3
Kaiser Permanente Downey/Bellflower Medical Center Oncology Clinics
Downey, California, United States, 90242
4
Kaiser Permanente Fontana Medical Center Oncology Clinic
Fontana, California, United States, 92335